Pharmacyte Biotech Inc (OTCMKTS:PMCB) is about to start the phase 2b clinical trial in pancreatic cancer. Before it initiates, the company wants its investors and customers to know some of the major milestones it’s working on and craves to attain down the line.
Milestones
Some of the major steps that Pharmacyte intends to take are as follows-
- Finalizing Trial Designs: With the support of a world-class team of oncologists, the company wants to finalize the design of the clinical trial. The prime objective of these trials is to get positive data that can lead the company to successful pancreatic cancer treatments.
- Formation of IND Team: The next focal point of the company is to form an IND team that can help it review the IND and submit the same to regulatory authorities. To make sure that things fall in line, Pharmacyte wants to put a group of domain experts in this team who can handle any situation.
- Pre-IND Meeting: The company wants to arrange a meeting with regulatory authorities to make sure that company’s products are approved within the given timeline. Pharmacyte doesn’t want to delay in promotion and marketing activities, which is why it’s paying 100% attention towards executing pre-IND meeting successfully.
- Other milestones that it wants to touch make room for clinical trial study sites, clinical protocols, and chemistry, control, and manufacturing information.
Stellar Biotechnologies Inc (OTCMKTS:SBOTD) has decided to give an update to all the shareholders concerning its listing on NASDAQ marketplace. It wants to communicate everything to shareholders in a clear-cut way, thus organizing a meeting on October 29, 2015. As per the reports, it looks forward to discussing various corporate governance requirements, which can be updated before the listing takes place.
USANA Health Sciences, Inc. (NYSE:USNA) has been shortlisted as one of the 50 companies that showed the highest growth rate in Utah area. It’s the 8th consecutive occasion when USANA has successfully made it to the Utah Business Fast 50 List.
